ALK and ovarian serous adenocarcinoma: This article reports a case of EML4‐ALK‐positive advanced low‐grade serous ovarian cancer (LGSOC) with intracranial metastasis that responded dramatically to a third‐generation ALK inhibitor, lorlatinib, with good therapeutic effect.